Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Leonard Bell sold 100 shares of the stock in a transaction on Tuesday, January 10th. The stock was sold at an average price of $144.99, for a total transaction of $14,499.00. Following the sale, the director now owns 403,719 shares of the company’s stock, valued at approximately $58,535,217.81. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Leonard Bell also recently made the following trade(s):

  • On Monday, January 9th, Leonard Bell sold 40,065 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $138.48, for a total transaction of $5,548,201.20.
  • On Friday, November 4th, Leonard Bell sold 37,317 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $140.38, for a total transaction of $5,238,560.46.
  • On Monday, October 31st, Leonard Bell sold 1,300 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $135.28, for a total transaction of $175,864.00.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.93 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $109.12 and a 12 month high of $169.84. The firm’s 50-day moving average is $122.56 and its 200-day moving average is $125.32. The firm has a market capitalization of $30.66 billion, a PE ratio of 83.49 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.19. The business had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The firm’s revenue was up 19.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.16 EPS. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $4.64 EPS for the current year.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Director Leonard Bell Sells 100 Shares of Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. and international copyright laws. The legal version of this story can be viewed at http://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-director-leonard-bell-sells-100-shares-of-stock/1061416.html.

Several analysts have recently commented on ALXN shares. FBR & Co restated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Monday, November 14th. Vetr cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 target price for the company. in a research note on Tuesday, October 18th. Jefferies Group reduced their target price on shares of Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating for the company in a research note on Friday, September 23rd. Oppenheimer Holdings, Inc. started coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, December 15th. They issued a “market perform” rating for the company. Finally, Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 28th. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $172.80.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in Alexion Pharmaceuticals by 651.0% in the second quarter. Meeder Asset Management Inc. now owns 6,121 shares of the biopharmaceutical company’s stock worth $715,000 after buying an additional 5,306 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Alexion Pharmaceuticals by 3.8% in the second quarter. Daiwa Securities Group Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $642,000 after buying an additional 200 shares during the last quarter. Bank of Montreal Can acquired a new position in Alexion Pharmaceuticals during the second quarter worth $34,314,000. Pitcairn Co. raised its position in Alexion Pharmaceuticals by 32.5% in the second quarter. Pitcairn Co. now owns 20,654 shares of the biopharmaceutical company’s stock worth $2,412,000 after buying an additional 5,068 shares during the last quarter. Finally, Strs Ohio raised its position in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares during the last quarter. 94.79% of the stock is currently owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.